Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: Is treatment response different between children and adolescents?
To compare clinical and health-related quality of life (HRQoL) outcomes between children and adolescents with ADHD treated with OROS® MPH, using data from two large similarly-designed multicenter, prospective, open-label, single-arm, non-interventional studies.